BridgeMD
Identification and clinical relevance of an oxytocin-deficient state: randomized, crossover, placebo-controlled pilot physiopathological study: GLP1 Study.
EU CTIS ID: 2024-515588-67-00
What this study is testing
Improve knowledge of endogenous OT secretion in patients with hypopituitarism and CS.
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age between 18 and 65 years.
- Patients with hypopituitarism (HIPO), defined as more than one pituitary hormone deficit, with at least one clinical sign of hypothalamic damage.
- Clinical signs of potential hypothalamic damage are considered to be the presence of at least one of the following: .central diabetes insipidus and/or severe obesity and/or hyperphagia and/or MRI suggestive of hypothalamic damage history of traumatic brain injury .history of irradiation of tumors affecting the hypothalamic region (e.g., craniopharyngioma, germinoma, etc.).
- HIPO patients must be on stable hormone replacement therapy for three months prior to the prior to the study.
- Participating women will make visits in follicular phase (between day 1 and 10 of the menstrual cycle) to minimize the effects of increased estradiol in other phases of the menstrual cycle on OT levels (23), and postmenopausal HIPO women will be compared with age-matched controls.
- Healthy controls (HC) balanced by body mass index (BMI, if possible), age and sex with HIPO patients sex with HIPO patients.
You likely can't join if
- Uncorrected hormone deficiency.
- Pregnancy or breastfeeding the 8 weeks before.
- Known allergies or hypersensitivity to GLP1 receptor analogues or to some of the excipients (methacresol mannitol, glacial acetic acid, sodium acetate trihydrate). excipients (methacresol mannitol, glacial acetic acid, sodium acetate trihydrate).
- Diabetes mellitus or under treatment with any diabetes drug.
- Pancreatitis.
- Patients under treatment with high doses of glucocorticoids (higher than substitute doses).
See the full eligibility criteria
Who can join
- Age between 18 and 65 years.
- Patients with hypopituitarism (HIPO), defined as more than one pituitary hormone deficit, with at least one clinical sign of hypothalamic damage.
- Clinical signs of potential hypothalamic damage are considered to be the presence of at least one of the following: .central diabetes insipidus and/or severe obesity and/or hyperphagia and/or MRI suggestive of hypothalamic damage history of traumatic brain injury .history of irradiation of tumors affecting the hypothalamic region (e.g., craniopharyngioma, germinoma, etc.).
- HIPO patients must be on stable hormone replacement therapy for three months prior to the prior to the study.
- Participating women will make visits in follicular phase (between day 1 and 10 of the menstrual cycle) to minimize the effects of increased estradiol in other phases of the menstrual cycle on OT levels (23), and postmenopausal HIPO women will be compared with age-matched controls.
- Healthy controls (HC) balanced by body mass index (BMI, if possible), age and sex with HIPO patients sex with HIPO patients.
What rules you out
- Uncorrected hormone deficiency.
- Pregnancy or breastfeeding the 8 weeks before.
- Known allergies or hypersensitivity to GLP1 receptor analogues or to some of the excipients (methacresol mannitol, glacial acetic acid, sodium acetate trihydrate). excipients (methacresol mannitol, glacial acetic acid, sodium acetate trihydrate).
- Diabetes mellitus or under treatment with any diabetes drug.
- Pancreatitis.
- Patients under treatment with high doses of glucocorticoids (higher than substitute doses).
- Potentially fertile women (after menarche and before postmenopause unless permanently sterilized by hysterectomy, salpinguectomy, or salpinguectomy. unless they have been permanently sterilized by hysterectomy, bilateral salpinguectomy and bilateral and bilateral oophorectomy) and are unwilling to take highly effective contraceptive measures during the study period highly effective contraceptive measures during the study period: combined contraceptive treatment with estrogens and progestogens associated with ovulation inhibition (oral, intravaginal, or (oral, intravaginal or transdermal), intrauterine device, sexual abstinence (abstinence from heterosexual intercourse) during the (abstinence from heterosexual intercourse) during the entire risk period associated with the study, taking into account the patient's or vascular the situation of the vasectomized patient or partner.
- Patients who refuse or are unable to give written informed consent.
- In addition, for CS: Presence of brain or pituitary tumor. Irradiation involving the hypothalamus or pituitary gland History of hypopituitarism History of hypopituitarism -History of testosterone, glucocorticoids or GLP1 receptor analogues. GLP1 RECEPTOR ANALOGUES.
- Creatinine >1.5mg/dL.
- ALT or AST >2.5x above the limit of normality.
- Hematocrit <30%.
- Active psychosis.
- Participation in clinical trials with experimental drugs in the last 30 days.
- Excessive physical activity.
- Alcohol intake in the 24 hours prior to study participation.
- Evidence of any acute illness or disease that the investigator determines may interfere with study participation and safety. interfere with study participation and safety.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.